Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

BTIG analyst Marvin Fong raised the firm’s price target on RealReal (REAL) to $5.50 from $4 and keeps a Buy rating on the shares. The firm ...

Fintel reports that on November 19, 2024, BTIG upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from Neutral ...

Energy and Infrastructure Transition Analyst Lewis holds a virtual meeting with management on November 22 hosted by BTIG. Don't Miss out on Research Tools: Discover the latest stocks recommended by ...

Fintel reports that on November 18, 2024, BTIG initiated coverage of VYNE Therapeutics (NasdaqCM:VYNE) with a Buy ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that its Digital Health Forum will take place on Monday, November 25, 2024. The event will be hosted by David Larsen, CFA, BTIG Healthcare IT and ...

On Thursday, BioNano Genomics Inc (BNGO) stock saw a decline, ending the day at $0.26 which represents a decrease of $-0.02 or -7.14% from the prior close of $0.28. The stock opened at $0.26 and ...

On Thursday, Opendoor Technologies Inc (OPEN) stock saw a decline, ending the day at $1.77 which represents a decrease of $-0.04 or -2.21% from the prior close of $1.81. The stock opened at $1.81 and ...

"The bond market is telling you that Trump's policies will be inflationary and you're going to have tariffs, so the direction of the 10-year yield is going to be the indicator for how the small caps ...

On Monday, Dream Finders Homes Inc. (NYSE:DFH) shares maintained Neutral rating by BTIG, following a third-quarter earnings per share (EPS) that fell short of expectations. Dream Finders Homes ...

Investing.com -- Fiverr (NYSE:FVRR) shares were down 4% in pre-open trade on Monday after BTIG downgraded its rating on the stock to "neutral" from "buy," citing a shift in the risk-reward profile ...

Investing.com -- Fiverr (NYSE:FVRR) shares were down 4% in pre-open trade on Monday after BTIG downgraded its rating on the stock to "neutral" from "buy," citing a shift in the risk-reward profile ...